Remission & chronicity
Biomarker Targets & Therapeutic Agents
Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: Clinical > Mechanistic > Correlative.
ACAN
Pipeline results not yet available for this target. Run the pipeline to populate.
ADAMTS5
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| ALDUMASTAT | ↓ inhibits | Mechanistic | DGIdb | |
| AGG-523 | ? unclear | Mechanistic | 560.0 nM (IC50) | DGIdb |
| RECOMBINANT TUMOR NECROSIS FACTOR FAMILY PROTEIN | ? unclear | Mechanistic | DGIdb | |
| CHEMBL208009 | ↓ inhibits | Mechanistic | 97.0 nM (Ki) | ChEMBL |
| CHEMBL207305 | ↓ inhibits | Mechanistic | 1900.0 nM (Ki) | ChEMBL |
| CHEMBL230403 | ↓ inhibits | Mechanistic | 20100.0 nM (IC50) | ChEMBL |
| CHEMBL396206 | ↓ inhibits | Mechanistic | 1800.0 nM (IC50) | ChEMBL |
| CHEMBL231000 | ↓ inhibits | Mechanistic | 1600.0 nM (IC50) | ChEMBL |
| CHEMBL230895 | ↓ inhibits | Mechanistic | 1300.0 nM (IC50) | ChEMBL |
| CHEMBL230789 | ↓ inhibits | Mechanistic | 11100.0 nM (IC50) | ChEMBL |
| CHEMBL230894 | ↓ inhibits | Mechanistic | 1300.0 nM (IC50) | ChEMBL |
| CHEMBL230788 | ↓ inhibits | Mechanistic | 1100.0 nM (IC50) | ChEMBL |
| CHEMBL387994 | ↓ inhibits | Mechanistic | 900.0 nM (IC50) | ChEMBL |
| CHEMBL230683 | ↓ inhibits | Mechanistic | 5300.0 nM (IC50) | ChEMBL |
| CHEMBL397040 | ↓ inhibits | Mechanistic | 6700.0 nM (IC50) | ChEMBL |
| CHEMBL397937 | ↓ inhibits | Mechanistic | 6800.0 nM (IC50) | ChEMBL |
| CHEMBL230726 | ↓ inhibits | Mechanistic | 9200.0 nM (IC50) | ChEMBL |
| CHEMBL230725 | ↓ inhibits | Mechanistic | 10000.0 nM (IC50) | ChEMBL |
| CHEMBL396218 | ↓ inhibits | Mechanistic | 5300.0 nM (IC50) | ChEMBL |
| CHEMBL230723 | ↓ inhibits | Mechanistic | 2500.0 nM (IC50) | ChEMBL |
| CHEMBL396217 | ↓ inhibits | Mechanistic | 3200.0 nM (IC50) | ChEMBL |
| CHEMBL230621 | ↓ inhibits | Mechanistic | 1700.0 nM (IC50) | ChEMBL |
| CHEMBL230620 | ↓ inhibits | Mechanistic | 14800.0 nM (IC50) | ChEMBL |
| CHEMBL395985 | ↓ inhibits | Mechanistic | 16200.0 nM (IC50) | ChEMBL |
| CHEMBL230619 | ↓ inhibits | Mechanistic | 4900.0 nM (IC50) | ChEMBL |
| CHEMBL230516 | ↓ inhibits | Mechanistic | 11600.0 nM (IC50) | ChEMBL |
| CHEMBL395503 | ↓ inhibits | Mechanistic | 3500.0 nM (IC50) | ChEMBL |
| CHEMBL230514 | ↓ inhibits | Mechanistic | 1400.0 nM (IC50) | ChEMBL |
| CHEMBL230408 | ↓ inhibits | Mechanistic | 1800.0 nM (IC50) | ChEMBL |
| CHEMBL232565 | ↓ inhibits | Mechanistic | 4200.0 nM (IC50) | ChEMBL |
| CHEMBL391693 | ↓ inhibits | Mechanistic | 9000.0 nM (IC50) | ChEMBL |
| CHEMBL442073 | ↓ inhibits | Mechanistic | 2100.0 nM (IC50) | ChEMBL |
| CHEMBL231740 | ↓ inhibits | Mechanistic | 1100.0 nM (IC50) | ChEMBL |
| CHEMBL232364 | ↓ inhibits | Mechanistic | 2500.0 nM (IC50) | ChEMBL |
| CHEMBL393113 | ↓ inhibits | Mechanistic | 2200.0 nM (IC50) | ChEMBL |
| CHEMBL392264 | ↓ inhibits | Mechanistic | 23200.0 nM (IC50) | ChEMBL |
| CHEMBL233333 | ↓ inhibits | Mechanistic | 9100.0 nM (IC50) | ChEMBL |
| CHEMBL391928 | ↓ inhibits | Mechanistic | 7100.0 nM (IC50) | ChEMBL |
| CHEMBL233132 | ↓ inhibits | Mechanistic | 4200.0 nM (IC50) | ChEMBL |
| CHEMBL393991 | ↓ inhibits | Mechanistic | 4600.0 nM (IC50) | ChEMBL |
Showing top 40 of 196 agents ranked by evidence tier.
COL2A1
CTNNB1
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| PP1 | ↓ inhibits | Mechanistic | DGIdb | |
| PF-670462 | ↓ inhibits | Mechanistic | DGIdb | |
| MPI-0479605 | ? unclear | Mechanistic | DGIdb | |
| SKF-86002 | ↓ inhibits | Mechanistic | DGIdb | |
| SB203580 | ↓ inhibits | Mechanistic | DGIdb | |
| IMATINIB | ? unclear | Mechanistic | DGIdb | |
| MAPK13-IN-1 | ↓ inhibits | Mechanistic | DGIdb | |
| BAY1217389 | ? unclear | Mechanistic | DGIdb | |
| NIROGACESTAT | ? unclear | Mechanistic | DGIdb | |
| NMS-P715 | ? unclear | Mechanistic | DGIdb | |
| ACUMAPIMOD | ↓ inhibits | Mechanistic | DGIdb | |
| EOSIN_Y | ? unclear | Mechanistic | DGIdb | |
| DILMAPIMOD | ↓ inhibits | Mechanistic | DGIdb | |
| PRI-724 | ↓ inhibits | Mechanistic | DGIdb | |
| MW150 | ↓ inhibits | Mechanistic | DGIdb | |
| COMPOUND 12 [PMID: 22521646] | ↓ inhibits | Mechanistic | DGIdb | |
| BMS-582949 | ↓ inhibits | Mechanistic | DGIdb | |
| OSUGACESTAT | ? unclear | Mechanistic | DGIdb | |
| AZD7624 | ↓ inhibits | Mechanistic | DGIdb | |
| VANTICTUMAB | ? unclear | Mechanistic | DGIdb | |
| ANTI-PD-L1 MONOCLONAL ANTIBODY | ? unclear | Mechanistic | DGIdb | |
| LOSMAPIMOD | ↓ inhibits | Mechanistic | DGIdb | |
| LENALIDOMIDE | ? unclear | Mechanistic | DGIdb | |
| NDPPC | ↓ inhibits | Mechanistic | DGIdb | |
| CELECOXIB | ? unclear | Mechanistic | DGIdb | |
| TRAMETINIB DIMETHYL SULFOXIDE | ? unclear | Mechanistic | DGIdb | |
| DORAMAPIMOD | ↓ inhibits | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL2172378 | ? unclear | Mechanistic | DGIdb | |
| RECOMBINANT HUMAN ENDOSTATIN | ? unclear | Mechanistic | DGIdb | |
| TRICIRIBINE | ? unclear | Mechanistic | DGIdb | |
| TEMSIROLIMUS | ? unclear | Mechanistic | DGIdb | |
| AZD6703 | ↓ inhibits | Mechanistic | DGIdb | |
| SAM68 MODULATOR CWP232291 | ? unclear | Mechanistic | DGIdb | |
| NEFLAMAPIMOD | ↓ inhibits | Mechanistic | DGIdb | |
| LETROZOLE | ? unclear | Mechanistic | DGIdb | |
| VX-702 | ↓ inhibits | Mechanistic | DGIdb | |
| 7-HYDROXYSTAUROSPORINE | ↓ inhibits | Mechanistic | DGIdb | |
| TAK-715 | ↓ inhibits | Mechanistic | DGIdb | |
| FLUORESCEIN SODIUM | ? unclear | Mechanistic | DGIdb | |
| PEXMETINIB | ↓ inhibits | Mechanistic | DGIdb |
Showing top 40 of 172 agents ranked by evidence tier.
IL1B
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| ASPIRIN | ? unclear | Mechanistic | DGIdb | |
| MAFOSFAMIDE | ? unclear | Mechanistic | DGIdb | |
| DIACETYLRHEIN | ? unclear | Mechanistic | DGIdb | |
| INFLIXIMAB | ? unclear | Mechanistic | DGIdb | |
| LANSOPRAZOLE | ? unclear | Mechanistic | DGIdb | |
| TILUDRONIC ACID | ? unclear | Mechanistic | DGIdb | |
| GEVOKIZUMAB | ~ modulates | Mechanistic | DGIdb | |
| LUTIKIZUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| CELASTROL | ? unclear | Mechanistic | DGIdb | |
| CYTARABINE | ? unclear | Mechanistic | DGIdb | |
| RILONACEPT | ↓ inhibits | Mechanistic | DGIdb | |
| TT-301 | ? unclear | Mechanistic | DGIdb | |
| METFORMIN | ? unclear | Mechanistic | DGIdb | |
| ANTICONVULSANT AGENT | ? unclear | Mechanistic | DGIdb | |
| ANTIDEPRESSANT AGENT | ? unclear | Mechanistic | DGIdb | |
| ACITRETIN | ? unclear | Mechanistic | DGIdb | |
| ERYTHROMYCIN | ? unclear | Mechanistic | DGIdb | |
| ALTEPLASE | ? unclear | Mechanistic | DGIdb | |
| OFLOXACIN | ? unclear | Mechanistic | DGIdb | |
| PENTOXIFYLLINE | ? unclear | Mechanistic | DGIdb | |
| USTEKINUMAB | ? unclear | Mechanistic | DGIdb | |
| LITHIUM | ? unclear | Mechanistic | DGIdb | |
| RALOXIFENE HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| MITOGEN-ACTIVATED PROTEIN KINASE INHIBITOR | ? unclear | Mechanistic | DGIdb | |
| DRUGSATFDA.NDA:008378 | ? unclear | Mechanistic | DGIdb | |
| NICARDIPINE | ? unclear | Mechanistic | DGIdb | |
| GLUCOSAMINE | ? unclear | Mechanistic | DGIdb | |
| BECLOMETHASONE DIPROPIONATE | ? unclear | Mechanistic | DGIdb | |
| PAREGORIC | ? unclear | Mechanistic | DGIdb | |
| CEFACLOR ANHYDROUS | ? unclear | Mechanistic | DGIdb | |
| IBUDILAST | ? unclear | Mechanistic | DGIdb | |
| MELATONIN | ? unclear | Mechanistic | DGIdb | |
| PENTAMIDINE | ? unclear | Mechanistic | DGIdb | |
| PRAVASTATIN SODIUM | ? unclear | Mechanistic | DGIdb | |
| VERAPAMIL | ? unclear | Mechanistic | DGIdb | |
| THYROGLOBULIN | ? unclear | Mechanistic | DGIdb | |
| RISEDRONIC ACID | ? unclear | Mechanistic | DGIdb | |
| AUTOANTIGEN | ? unclear | Mechanistic | DGIdb | |
| CDP-484 | ↓ inhibits | Mechanistic | DGIdb | |
| ETIDRONIC ACID | ? unclear | Mechanistic | DGIdb |
Showing top 40 of 218 agents ranked by evidence tier.
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| CISPLATIN | ? unclear | Mechanistic | DGIdb | |
| ZILTIVEKIMAB | ~ modulates | Mechanistic | DGIdb | |
| CHINESE HERBS | ? unclear | Mechanistic | DGIdb | |
| PF-04236921 | ↓ inhibits | Mechanistic | DGIdb | |
| MRA 003 US | ↓ inhibits | Mechanistic | DGIdb | |
| SIGNAL TRANSDUCTION INHIBITOR | ? unclear | Mechanistic | DGIdb | |
| BINETRAKIN | ? unclear | Mechanistic | DGIdb | |
| IBUDILAST | ? unclear | Mechanistic | DGIdb | |
| INSULIN, REGULAR, HUMAN | ? unclear | Mechanistic | DGIdb | |
| SILTUXIMAB | ↓ inhibits | Mechanistic | DGIdb | |
| METRONIDAZOLE | ? unclear | Mechanistic | DGIdb | |
| CLAZAKIZUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| GALLIUM NITRATE | ? unclear | Mechanistic | DGIdb | |
| INTERFERON ALFA-2B | ? unclear | Mechanistic | DGIdb | |
| DULOXETINE HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| MEDI-5117 | ↓ inhibits | Mechanistic | DGIdb | |
| GEMFIBROZIL | ? unclear | Mechanistic | DGIdb | |
| BIAFINE CREAM | ? unclear | Mechanistic | DGIdb | |
| ETANERCEPT | ? unclear | Mechanistic | DGIdb | |
| ELSILIMOMAB | ↓ inhibits | Mechanistic | DGIdb | |
| SAQUINAVIR | ? unclear | Mechanistic | DGIdb | |
| INFLIXIMAB | ? unclear | Mechanistic | DGIdb | |
| LINEZOLID | ? unclear | Mechanistic | DGIdb | |
| IFOSFAMIDE | ? unclear | Mechanistic | DGIdb | |
| OLOKIZUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| HMG-COA REDUCTASE INHIBITOR | ? unclear | Mechanistic | DGIdb | |
| MIDOSTAURIN | ? unclear | Mechanistic | DGIdb | |
| SELENIUM | ? unclear | Mechanistic | DGIdb | |
| SIRUKUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| PEGINTERFERON ALFA-2B | ? unclear | Mechanistic | DGIdb | |
| ECHINACEA PREPARATION | ? unclear | Mechanistic | DGIdb | |
| ENZYME INHIBITOR | ? unclear | Mechanistic | DGIdb | |
| FENOFIBRATE MICRONIZED | ? unclear | Mechanistic | DGIdb | |
| VITAMIN K | ? unclear | Mechanistic | DGIdb | |
| PEGINTERFERON ALFA-2A | ? unclear | Mechanistic | DGIdb | |
| RIBAVIRIN | ? unclear | Mechanistic | DGIdb | |
| VITAMIN A PALMITATE | ? unclear | Mechanistic | DGIdb | |
| ARSENIC TRIOXIDE | ? unclear | Mechanistic | DGIdb | |
| DIHYDROSPHINGOSINE | ? unclear | Mechanistic | DGIdb | |
| LEVOFLOXACIN ANHYDROUS | ? unclear | Mechanistic | DGIdb |
Showing top 40 of 173 agents ranked by evidence tier.
MMP13
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| CURCUMIN | ? unclear | Mechanistic | DGIdb | |
| REBIMASTAT | ↓ inhibits | Mechanistic | DGIdb | |
| DOXYCYCLINE CALCIUM | ↓ inhibits | Mechanistic | DGIdb | |
| APRATASTAT | ↓ inhibits | Mechanistic | DGIdb | |
| PRINOMASTAT | ? unclear | Mechanistic | 1.5 nM (IC50) | DGIdb |
| DOXYCYCLINE ANHYDROUS | ↓ inhibits | Mechanistic | DGIdb | |
| CTS-1027 | ↓ inhibits | Mechanistic | 2.0 nM (IC50) | DGIdb |
| ILOMASTAT | ? unclear | Mechanistic | DGIdb | |
| DOXYCYCLINE HYCLATE | ? unclear | Mechanistic | Open Targets | |
| DOXYCYCLINE | ? unclear | Mechanistic | Open Targets | |
| CHEMBL348210 | ↓ inhibits | Mechanistic | 3.0 nM (IC50) | ChEMBL |
| CHEMBL80814 | ↓ inhibits | Mechanistic | 2.0 nM (IC50) | ChEMBL |
| CHEMBL346624 | ↓ inhibits | Mechanistic | 0.7 nM (IC50) | ChEMBL |
| CHEMBL276119 | ↓ inhibits | Mechanistic | 2.0 nM (IC50) | ChEMBL |
| CHEMBL78934 | ↓ inhibits | Mechanistic | 5.0 nM (IC50) | ChEMBL |
| CHEMBL78369 | ↓ inhibits | Mechanistic | 1.0 nM (IC50) | ChEMBL |
| CGS-27023A | ↓ inhibits | Mechanistic | 8.0 nM (IC50) | ChEMBL |
| CHEMBL151591 | ↓ inhibits | Mechanistic | 3.0 nM (IC50) | ChEMBL |
| CHEMBL80453 | ↓ inhibits | Mechanistic | 4.0 nM (IC50) | ChEMBL |
| CHEMBL312432 | ↓ inhibits | Mechanistic | 6.0 nM (IC50) | ChEMBL |
| CHEMBL150655 | ↓ inhibits | Mechanistic | 0.2 nM (IC50) | ChEMBL |
| CHEMBL306617 | ↓ inhibits | Mechanistic | 2.0 nM (IC50) | ChEMBL |
| CHEMBL79111 | ↓ inhibits | Mechanistic | 2.0 nM (IC50) | ChEMBL |
| CHEMBL78798 | ↓ inhibits | Mechanistic | 1.0 nM (IC50) | ChEMBL |
| CHEMBL440355 | ↓ inhibits | Mechanistic | 0.5 nM (IC50) | ChEMBL |
| CHEMBL80969 | ↓ inhibits | Mechanistic | 2.0 nM (IC50) | ChEMBL |
| CHEMBL78909 | ↓ inhibits | Mechanistic | 1.0 nM (IC50) | ChEMBL |
| CHEMBL76137 | ↓ inhibits | Mechanistic | 3.0 nM (IC50) | ChEMBL |
| CHEMBL310340 | ↓ inhibits | Mechanistic | 1.4 nM (IC50) | ChEMBL |
| CHEMBL150027 | ↓ inhibits | Mechanistic | 0.4 nM (IC50) | ChEMBL |
| CHEMBL346442 | ↓ inhibits | Mechanistic | 0.2 nM (IC50) | ChEMBL |
| CHEMBL76836 | ↓ inhibits | Mechanistic | 3.0 nM (IC50) | ChEMBL |
| CHEMBL150077 | ↓ inhibits | Mechanistic | 0.3 nM (IC50) | ChEMBL |
| CHEMBL357796 | ↓ inhibits | Mechanistic | 8.0 nM (IC50) | ChEMBL |
| CHEMBL312429 | ↓ inhibits | Mechanistic | 2.0 nM (IC50) | ChEMBL |
| CHEMBL78549 | ↓ inhibits | Mechanistic | 1.0 nM (IC50) | ChEMBL |
| CHEMBL78508 | ↓ inhibits | Mechanistic | 2.0 nM (IC50) | ChEMBL |
| CHEMBL80732 | ↓ inhibits | Mechanistic | 2.0 nM (IC50) | ChEMBL |
| CHEMBL309311 | ↓ inhibits | Mechanistic | 1.0 nM (IC50) | ChEMBL |
| CHEMBL151399 | ↓ inhibits | Mechanistic | 4.0 nM (IC50) | ChEMBL |
Showing top 40 of 198 agents ranked by evidence tier.
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| MEDI-578 | ↓ inhibits | Mechanistic | DGIdb | |
| CERE-110 | ? unclear | Mechanistic | DGIdb | |
| FASINUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| TANEZUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| FRUNEVETMAB | ~ modulates | Mechanistic | DGIdb | |
| FULRANUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| BEDINVETMAB | ~ modulates | Mechanistic | DGIdb | |
| PG-110 | ↓ inhibits | Mechanistic | DGIdb | |
| CHEMBL1397270 | ↓ inhibits | Mechanistic | 1000.0 nM (IC50) | ChEMBL |
PTGS2
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| CARPROFEN | ↓ inhibits | Mechanistic | 102.0 nM (IC50) | DGIdb |
| INDOMETHACIN SODIUM | ↓ inhibits | Mechanistic | DGIdb | |
| DARBUFELONE | ? unclear | Mechanistic | DGIdb | |
| MEFENAMIC ACID | ↓ inhibits | Mechanistic | DGIdb | |
| MECLOFENAMATE SODIUM | ↓ inhibits | Mechanistic | DGIdb | |
| DICLOFENAC SODIUM | ↓ inhibits | Mechanistic | DGIdb | |
| CAPECITABINE | ? unclear | Mechanistic | DGIdb | |
| PIRPROFEN | ↓ inhibits | Mechanistic | DGIdb | |
| ESFLURBIPROFEN | ↓ inhibits | Mechanistic | DGIdb | |
| SULFASALAZINE | ↓ inhibits | Mechanistic | DGIdb | |
| BROMFENAC | ? unclear | Mechanistic | DGIdb | |
| IBUPROFEN, SODIUM SALT | ↓ inhibits | Mechanistic | DGIdb | |
| ALOXIPRIN | ↓ inhibits | Mechanistic | DGIdb | |
| TENOXICAM | ? unclear | Mechanistic | DGIdb | |
| FLURBIPROFEN | ↓ inhibits | Mechanistic | DGIdb | |
| SALICYLIC ACID | ? unclear | Mechanistic | DGIdb | |
| ATENOLOL | ? unclear | Mechanistic | DGIdb | |
| DEXKETOPROFEN | ↓ inhibits | Mechanistic | DGIdb | |
| ETORICOXIB | ↓ inhibits | Mechanistic | DGIdb | |
| LUMIRACOXIB | ↓ inhibits | Mechanistic | DGIdb | |
| SUPROFEN | ↓ inhibits | Mechanistic | DGIdb | |
| NS-398 | ? unclear | Mechanistic | DGIdb | |
| NABUMETONE | ↓ inhibits | Mechanistic | DGIdb | |
| URSOLIC ACID | ? unclear | Mechanistic | DGIdb | |
| IBUPROFEN LYSINE | ↓ inhibits | Mechanistic | DGIdb | |
| ACECLOFENAC | ↓ inhibits | Mechanistic | DGIdb | |
| IBUFENAC | ↓ inhibits | Mechanistic | DGIdb | |
| BALSALAZIDE | ? unclear | Mechanistic | DGIdb | |
| DIFLUNISAL | ↓ inhibits | Mechanistic | DGIdb | |
| BALSALAZIDE DISODIUM | ↓ inhibits | Mechanistic | DGIdb | |
| VACCINE | ? unclear | Mechanistic | DGIdb | |
| KETOROLAC TROMETHAMINE | ↓ inhibits | Mechanistic | DGIdb | |
| BENZYDAMINE HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| TIAPROFENIC ACID | ? unclear | Mechanistic | DGIdb | |
| RALOXIFENE HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| NAPROXCINOD | ↓ inhibits | Mechanistic | DGIdb | |
| IGURATIMOD | ↓ inhibits | Mechanistic | DGIdb | |
| ETODOLAC | ↓ inhibits | Mechanistic | DGIdb | |
| DICLOFENAC ETALHYALURONATE SODIUM | ↓ inhibits | Mechanistic | DGIdb | |
| ROFECOXIB | ↓ inhibits | Mechanistic | 530.0 nM (IC50) | DGIdb |
Showing top 40 of 299 agents ranked by evidence tier.
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| NERELIMOMAB | ↓ inhibits | Mechanistic | DGIdb | |
| CROMOLYN SODIUM | ? unclear | Mechanistic | DGIdb | |
| PLACULUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| METHYLENE BLUE | ? unclear | Mechanistic | DGIdb | |
| ALTEPLASE | ? unclear | Mechanistic | DGIdb | |
| CARBOPLATIN | ? unclear | Mechanistic | DGIdb | |
| GENTAMICIN | ? unclear | Mechanistic | DGIdb | |
| GOLIMUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| BUPIVACAINE | ? unclear | Mechanistic | DGIdb | |
| PENTOXIFYLLINE | ? unclear | Mechanistic | 85000.0 nM (IC50) | DGIdb |
| BENZO[E]PYRENE | ? unclear | Mechanistic | DGIdb | |
| THALIDOMIDE | ? unclear | Mechanistic | DGIdb | |
| PYRAZINAMIDE | ? unclear | Mechanistic | DGIdb | |
| GLIMEPIRIDE | ? unclear | Mechanistic | DGIdb | |
| OMEPRAZOLE | ? unclear | Mechanistic | DGIdb | |
| LENERCEPT | ↓ inhibits | Mechanistic | DGIdb | |
| ADALIMUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| PRAZOSIN HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| REMTOLUMAB | ? unclear | Mechanistic | DGIdb | |
| MIDOSTAURIN | ? unclear | Mechanistic | DGIdb | |
| LENABASUM | ? unclear | Mechanistic | DGIdb | |
| MAGNESIUM SULFATE ANHYDROUS | ? unclear | Mechanistic | DGIdb | |
| PICIBANIL | ? unclear | Mechanistic | DGIdb | |
| FLUOCINOLONE ACETONIDE | ? unclear | Mechanistic | DGIdb | |
| MILTEFOSINE | ? unclear | Mechanistic | DGIdb | |
| HOMIDIUM BROMIDE | ? unclear | Mechanistic | DGIdb | |
| OZORALIZUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| PEGSUNERCEPT | ↓ inhibits | Mechanistic | DGIdb | |
| CERTOLIZUMAB PEGOL | ↓ inhibits | Mechanistic | DGIdb | |
| THERAPEUTIC HORMONE | ? unclear | Mechanistic | DGIdb | |
| NAFAMOSTAT | ? unclear | Mechanistic | DGIdb | |
| FOLIC ACID | ? unclear | Mechanistic | DGIdb | |
| ABBV-257 | ? unclear | Mechanistic | DGIdb | |
| RISPERIDONE | ? unclear | Mechanistic | DGIdb | |
| COVA322 | ? unclear | Mechanistic | DGIdb | |
| HYDROXYCHLOROQUINE | ? unclear | Mechanistic | DGIdb | |
| CERTOLIZUMAB | ? unclear | Mechanistic | DGIdb | |
| AN0128 | ? unclear | Mechanistic | DGIdb | |
| 5,7-DIHYDROXY-4-METHYLCOUMARIN | ? unclear | Mechanistic | DGIdb | |
| SORAFENIB | ? unclear | Mechanistic | DGIdb |
Showing top 40 of 277 agents ranked by evidence tier.
Clinical Trials
Drug, biologic and supplement trials (treatment or prevention) from ClinicalTrials.gov whose main condition is Osteoarthritis: recruiting, active or completed, most recently updated first. Data retrieved 2026-10-28.
This multicenter, prospective, randomized, active-controlled, single-blind (assessor-blinded) clinical trial aims to evaluate the efficacy and safety of intra-articular injection of autologous adipose-derived mesenchymal stem cells (ADMSCs) compared with active comparator hyaluronic acid (HA) in pat...
The goal of this clinical trial is to determine the appropriate Bispectral Index (BIS) range and propofol effect-site concentration required to maintain adequate anesthesia depth during total intravenous anesthesia (TIVA) combined with midazolam, dexmedetomidine, or esketamine in patients undergoing...
Approximately 25 participants aged 18-70 years, with knee pain rated 4-7 on a 10-point visual analogue scale (VAS) and a disease duration of 6 months to 10 years, will be enrolled. The study has two parts. In Part 1, participants receive a single intra-articular injection of 1.0 mL, 1.5 mL or 2.0 mL...
This phase 2a trial is an international, multicenter, randomized, double-blind, placebo-controlled trial to investigate the efficacy and safety of one single intra-articular (IA) injection of 4P004 or placebo in: * patients between 40 and 80 years of age, * with synovitis and grade 2 to 4 osteoarthr...
This randomized, controlled, double-blind, three-arm parallel clinical trial will evaluate the efficacy and safety of undenatured type II collagen products on joint pain in adults diagnosed with knee osteoarthritis. Participants will be randomized to Nuvicol II (nuvicol® II), Nuvicol SII (nuvicol® S...
Each year, approximately 75,000 Canadians undergo knee replacement surgery, and up to 25% develop persistent post-surgical pain. Persistent post-surgical pain is associated with depression, anxiety, unemployment, and reduced quality of life. Chronic pain after surgery is often managed with opioid th...
The goal of this clinical trial is to compare the therapeutic effects of lyophilized platelet-rich plasma lysate and dextrose prolotherapy in patients with knee osteoarthritis (OA). The main questions it aims to answer are: * Does lyophilized platelet-rich plasma lysate improve pain, physical functi...
The goal of this clinical trial is to examine the effects of duloxetine on walking ability and physical activity in patients with knee osteoarthritis. Researchers will compare duloxetine to a placebo (a look-alike substance that contains no drug) to see if duloxetine works to improve walking ability...
This study aims to understand the safety, drug concentration and distribution of an intra-articular injectable formulation of celecoxib, AVD275, in patients with knee osteoarthritis. One single injection at three different doses of the drug will be studied in a sequential order, and each participant...
A Randomized, Double-Blind, Placebo-Controlled, Single Dose Study to Assess the Safety and Efficacy of SL1002 for the Treatment of Knee Pain in Patients with Osteoarthritis of the Knee.
This is a multicenter, prospective, randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of intra-articular administration of PTP-001 (MOTYS) for the treatment of knee osteoarthritis. The purpose of the trial is to evaluate the efficacy, safety, and tolerability of a single intr...
This trial will study the safety and efficacy of cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells delivered intravenously and intraarticularly for the treatment of Osteoarthritis.
This study is being done to find out if metformin is effective at reducing pain by delaying the onset of post-traumatic osteoarthritis (PTOA) after anterior cruciate ligament (ACL) reconstruction. This research study will compare metformin to placebo. The placebo tablet looks exactly like metformin,...
To evaluate the efficacy and safety of different doses of triamcinolone for local infiltration analgesia during total knee replacement
This is a multicenter, randomized, double-blind, placebo-controlled, Phase IIb study to evaluate intra-articular (IA) injections of Allocetra in participants with moderate-to-severe age related symptomatic primary knee osteoarthritis (OA).
Agents Found By Disease-Level Search
Searched directly from “Osteoarthritis” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 10-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).
49 agents shown (approved or with trial evidence) — 48 not found by the gene-target search above.
transient immune-modulationNOT in gene-target list
FX006 32 mgNOT in gene-target list
TCA IR 40 mgNOT in gene-target list
DELTA Revision acetabular cupNOT in gene-target list
Ketoprofen Topical Patch , 20%NOT in gene-target list
MPact CupNOT in gene-target list
YYD302 2mlNOT in gene-target list
YYD302 3mlNOT in gene-target list
GNSC-001NOT in gene-target list
Fit & Strong!NOT in gene-target list
Wait listNOT in gene-target list
tai chiNOT in gene-target list
Corticosteroid injection (CSI)NOT in gene-target list
stem cell injectionNOT in gene-target list
Autologous cell therapyNOT in gene-target list
Operative (partial arthroscopy)NOT in gene-target list
Conservative (diagnostic arthroscopy)NOT in gene-target list
chondroitin sulfateNOT in gene-target list
celecoxib
Non-image-based Computer-Assisted Navigation with Bone MorphingNOT in gene-target list
P.F.C. Sigma KneeNOT in gene-target list
Sodium Hyaluronate (Hyalgan)NOT in gene-target list
Osteotomy aloneNOT in gene-target list
Medacta GMK Sphere® Medial Knee ProsthesisNOT in gene-target list
TriathlonNOT in gene-target list
Total knee replacement with the ROCC® knee prosthesisNOT in gene-target list
Vitamin DNOT in gene-target list
Total Hip ArthroplastyNOT in gene-target list
OraVescent FentanylNOT in gene-target list
Aquamid reconstructionNOT in gene-target list
Stem Cell Support FormulaNOT in gene-target list
Zimmer Patient specific instrumentsNOT in gene-target list
Standard instrumentationNOT in gene-target list
barbed sutureNOT in gene-target list
standard sutureNOT in gene-target list
Tapentadol (CG5503) Extended Release (ER)NOT in gene-target list
Synvisc-One (hylan G-F 20)NOT in gene-target list
Vivacit-E LinerNOT in gene-target list
Liposomal bupivacaineNOT in gene-target list
Interscalene Nerve BlockNOT in gene-target list
BioPolyNOT in gene-target list
Electrotherapy groupNOT in gene-target list
Evicel fibrin sealantNOT in gene-target list
Traumeel® / Zeel® Injectable SolutionNOT in gene-target list
injection of Filtered Autologous Adipose TissueNOT in gene-target list
lorecivivint (SM04690)NOT in gene-target list
ESWTNOT in gene-target list
Nudge interventionNOT in gene-target list
CATALYSTEMNOT in gene-target list
Generated by the Open Source Medicine Foundation Biomarker Pipeline — 2026-10-08. Data sources: DGIdb, Open Targets, ChEMBL, PubMed, ClinicalTrials.gov. Not medical advice.